Bionoid Pharma, Inc. Rebrands as AI Maverick Intel, Inc. to Reflect Strategic Shift Toward AI-Driven Innovation
-
Gauff into round four at US Open after straight-set win
-
Prince William to represent King Charles III at Norway late King Harald's funeral
-
Bordeaux hammer Racing in Top 14 start as Bielle-Biarrey extends deal
-
Inter and Roma roar back to win thrillers and share top spot
-
Zheng, Potapova pull off upsets to reach US Open last 16
-
Don't stop them now: fans party for Freddie Mercury's 80th birthday
-
Swiatek into US Open fourth round in tight two-setter
-
AFP photographer wins top prize for Madagascar protest coverage
-
Werro wins in Brussels, as Russell and Dos Santos shine
-
Keys: 'I felt like I couldn't play tennis'
-
Kolbe breaks jaw and shoulder injury sidelines Savea
-
Simmonds stars as Pau upset Montpellier
-
US military strikes oil tankers as Iran vows tougher reprisals
-
Inter roar back in five-goal thriller with Napoli
-
Zheng rallies to stun Keys, Anisimova out in US Open third round
-
Haaland keeps Man City perfect in Premier League, blunt Spurs held
-
Bayern held to draw by stubborn Schalke
-
Hamilton worried by Ferrari pace while Antonelli prepares for a fight
-
Lens lose again ahead of Champions League date
-
Vuelta stage 15 shortened due to extreme heat, Mas consolidates lead
-
Olympic champion Zheng storms home to reach US Open last 16
-
Putin meets US envoys for Ukraine war talks
-
Big-spending Spurs must make better attacking decisions, says De Zerbi
-
Modric available for Croatia in Nations League
-
South Africa dominate New Zealand in second half to lead series
-
Potapova upsets 2025 US Open runner-up Anisimova
-
Kiefer Sutherland still in action, but ibuprofen lending helping hand
-
Gasly a 'class act' says Alpine boss after Monza pole
-
'Are we ready?' Oasis film captures band's frosty reunion
-
Athletic Bilbao crush Simeone's flat Atletico
-
Commemoration held for late Bosnian Serb war criminal Ratko Mladic
-
Stay far from battlefield, warns Japanese director in Vietnam War film
-
Haaland keeps new-look Man City perfect in Premier League, blunt Spurs held
-
Tens of thousands of Croatians protest over hazardous waste
-
Alpine's Gasly takes shock pole for Italian Grand Prix
-
Haaland heads unconvincing Man City top of Premier League
-
Nwaneri helps Dortmund to comeback win on Bundesliga debut
-
US envoys in Moscow as Russia and Ukraine vow not to hit capitals during talks
-
US military says destroys Iranian oil tankers after missile attacks
-
Motorsport governing body rejects Alpine boss's claims of bias
-
US envoys in Moscow for Ukraine war negotiations
-
US envoy on West Bank visit says Israel has responsibility for Palestinians
-
Commemoration held for late Serbian war criminal Ratko Mladic
-
Ethiopian Miss World contestant spotlights pain of sister's murder
-
Russell on top ahead of Hamilton in final Italian GP practice
-
'Leader' Raphinha rising to Barca striker challenge
-
Motorsport governing body rejects Alpine boss's claims of impartiality
-
Oasis fans gather in Venice for band reunion film
-
Flick hoping Barca's Yamal can face Valencia after knock
-
Two Nepal rescues revive hopes 10 days after flood
Bionoid Pharma, Inc. Rebrands as AI Maverick Intel, Inc. to Reflect Strategic Shift Toward AI-Driven Innovation
NEW YORK CITY, NEW YORK / ACCESS Newswire / May 16, 2025 / Bionoid Pharma Inc. (OTC PINK:BINP) proudly announces its corporate rebranding to AI Maverick Intel, Inc., marking a significant transformation in its strategic direction. This change underscores the company's commitment to leveraging advanced artificial intelligence technologies to revolutionize customer acquisition and engagement across healthcare, biotech, and other sectors.
The rebranding follows the successful acquisition of AI Maverick Intel, a leading platform renowned for its proprietary AI solutions that automate and enhance audience engagement. The platform's capabilities enable intelligent, two-way communication and data-driven interactions, positioning the company at the forefront of AI-driven business solutions.
"Our evolution into AI Maverick Intel, Inc. signifies more than a name change; it represents our dedication to pioneering AI technologies that drive meaningful engagement and sustainable growth," said Wayne Cockburn, CEO of AI Maverick Intel, Inc. "By integrating cutting-edge AI solutions, we are poised to deliver unparalleled value to our clients and stakeholders."
The company's flagship AI Maverick platform is designed to streamline customer acquisition processes, enabling businesses to identify, reach, and engage their target audiences with unprecedented efficiency and precision. This strategic shift aligns with the company's vision to become a leader in AI-driven solutions that foster innovation and long-term value creation.
For more information about AI Maverick Intel, Inc. and its innovative AI solutions, please visit https://aimaverickintel.com/
About Bionoid Pharma Inc.
Bionoid Pharma Inc. is a growth-oriented AI company focused on acquiring and enhancing revenue-generating businesses through its proprietary AI Maverick platform. The technology enables intelligent, two-way communication and data-driven engagement across healthcare, biotech, and other sectors. Bionoid aims to deliver long-term value through innovation, efficiency, and strategic partnerships.
Stay Connected:
Website | AI Maverick | OTC:BINP | X: @BionoidPharminc
Media Contact:
Wayne Cockburn, CEO
(905) 505-0770
Email: [email protected]
SOURCE: Bionoid Pharma Inc.
View the original press release on ACCESS Newswire
A.Jones--AMWN
